Navigation Links
Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Date:8/14/2008

SAN FRANCISCO, Aug. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced financial results for the three and six months ended June 30, 2008.

Net operating loss for the three months ended June 30, 2008 was $3.8 million or $0.16 per share compared to $1.5 million or $0.11 per share, for the same period of 2007. Net operating loss for the six months ended June 30, 2008 totaled $6.8 million or $0.28 per share compared to $2.2 million or $0.16 for the same period of 2007. Weighted average shares outstanding for the three months ended June 30, 2008 and 2007 were 24.1 million and 13.8 million, respectively. For the six months ended June 30, 2008 and 2007, weighted average shares outstanding were 24.1 million and 13.8 million, respectively.

Nile reported no revenue for the three and six months ended June 30, 2008 and 2007, respectively. Research and development expenses were $2.9 million for the three months ended June 30, 2008 compared to $0.9 million for the comparable period of 2007. For the six months ended June 30, 2008, research and development expenses totaled $4.9 million compared with $1.4 million for the same period of 2007. General and administrative expenses were $1.0 million for the three months ended June 30, 2008 compared to $0.6 million for the comparable period of 2007. For the six months ended June 30, 2008, general and administrative expenses totaled $2.2 million compared with $0.7 million for the same period of 2007.

At June 30, 2008, Nile had cash and cash equivalents of $10.3 million compared to $16.2 million on December 31, 2007. This $5.9 million decrease occurred as cash was used for operations.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Platelets, the tiny cell fragments whose job it is ... a cell nucleus. But they can "feel" the physical ... have discovered. , Platelets respond to surfaces with greater ... they "turn on" other platelets and other components of ... smarter than we give them credit for, in that ...
(Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 years ... suffering, restoring hope an quality of life and contributing ... because of the innovative cellular biomedicines research that made ... , The company was founded in 1994 in ... chief of research, and Topricin inventor), Aurora Paradise (COO) ...
(Date:9/22/2014)... 2014 Invisible Sentinel Inc., a ... food and beverage industries, announced today that its ... a non-exclusive agreement by Enartis, a global provider ... an Esseco Group company headquartered in Trecate, Italy, ... and other global markets for their own in-winery ...
Breaking Biology Technology:Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
... Matrox Graphics Inc., the leading,manufacturer of specialized ... Matrox Xenia(TM) Series display controller boards with its,ME/CCL ... first native PCI Express single-slot board with,all-digital, triple-monitor ... configuration. Xenia Series supports resolutions from <1MP to,8MP ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today ... presentation of favorable data,generated by scientists at Amgen, ... scheduled presentation by Dr. Paul Pevsner of the,NYU ... in identifying potential protein,biomarkers in colon cancer samples, ...
... 8 Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical ... President and Chief Financial Officer,is scheduled to present ... in New York City on Monday, October 13, ... webcast of the presentation will be available at, ...
Cached Biology Technology:Totoku Europe Chooses Matrox Xenia(TM) Series to Drive Medical Monitors 2Pressure BioSciences, Inc. Provides Corporate Update 2Pressure BioSciences, Inc. Provides Corporate Update 3Pressure BioSciences, Inc. Provides Corporate Update 4Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
(Date:9/22/2014)... Yale University researchers are studying a potential new treatment ... disease in which scars develop in the lungs and ... mimic, miR-29, which is delivered to lung tissue intravenously. ... it reversed fibrosis after several days. , The ... EMBO Molecular Medicine . , "The mimic, when injected ...
(Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
(Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" ... also suffer an unfortunate side effect, researchers report: ... bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences . ... undesirable consequence of the evolution of antifreeze proteins ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... single dose of gene-virus combination cured rats of a ... causes the accumulation of bilirubin –which, untreated, results in ... of Medicine in a report in the Proceedings of ... first time this disease (Crigler-Najjar syndrome) has been completely ...
... new approach to predict whether a drug in development ... could get antibiotics to market faster and more cheaply, ... scientists worldwide have sounded the alarm: There simply aren’t ... adept at outwitting the traditional antibiotic arsenal. , Yet ...
... variation that may increase susceptibility to osteoporosis, a new study ... Louis demonstrated that in women the variant gene speeds up ... in the bones of the hip. , The study will ... Bone and Mineral Research and is available online. , ...
Cached Biology News:Gene Therapy Cures Inherited Liver Disease In Rats 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 3New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 4Increased risk of osteoporosis associated with gene that one in five people have 2
...
Ras-related C3 botulinum toxin substrate 1...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: